Sclerostin Antibody Treatment Improves Fracture Outcomes in a Type I Diabetic Mouse Model

Type 1 diabetes mellitus (T1DM) patients have osteopenia and impaired fracture healing due to decreased osteoblast activity. Further, no adequate treatments are currently available that can restore impaired healing in T1DM; hence a significant need exists to investigate new therapeutics for treatmen...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Bone
Autors principals: Yee, Cristal S., Xie, LiQin, Hatsell, Sarah, Hum, Nicholas, Murugesh, Deepa, Economides, Aris N., Loots, Gabriela G., Collette, Nicole M.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4635060/
https://ncbi.nlm.nih.gov/pubmed/25952969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bone.2015.04.048
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars